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duced physical performance reduces quality of life in patients with
chronic obstructive pulmonary disease (COPD). Impaired physical per-
formance is, in part, a consequence of reduced muscle mass and function,
which is accompanied by mitochondrial dysfunction. We recently
showed that miR-542-3p and miR-542-5p were elevated in a small cohort
of COPD patients and more markedly in critical care patients. In mice,
these microRNAs (miRNAs) promoted mitochondrial dysfunction sug-
gesting that they would affect physical performance in patients with
COPD, but we did not explore the association of these miRNAs with
disease severity or physical performance further. We therefore quantified
miR-542-3p/5p and mitochondrial rRNA expression in RNA extracted
from quadriceps muscle of patients with COPD and determined their
association with physical performance. As miR-542-3p inhibits ribo-
somal protein synthesis its ability to inhibit protein synthesis was also
determined in vitro. Both miR-542-3p expression and -5p expression
were elevated in patients with COPD (5-fold P  0.001) and the degree
of elevation associated with impaired lung function (transfer capacity of
the lung for CO in % and forced expiratory volume in 1 s in %) and
physical performance (6-min walk distance in %). In COPD patients, the
ratio of 12S rRNA to 16S rRNA was suppressed suggesting mitochon-
drial ribosomal stress and mitochondrial dysfunction and miR-542-3p/5p
expression was inversely associated with mitochondrial gene expression
and positively associated with p53 activity. miR-542-3p suppressed
RPS23 expression and maximal protein synthesis in vitro. Our data show
that miR-542-3p and -5p expression is elevated in COPD patients and
may suppress physical performance at least in part by inhibiting mito-
chondrial and cytoplasmic ribosome synthesis and suppressing
protein synthesis.
NEW & NOTEWORTHY miR-542-3p and -5p are elevated in the
quadriceps muscle of patients with chronic obstructive pulmonary
disease (COPD) in proportion to the severity of their lung disease.
These microRNAs inhibit mitochondrial and cytoplasmic protein
synthesis suggesting that they contribute to impaired exercise perfor-
mance in COPD.
chronic obstructive pulmonary disease; microRNA; mitochondrial
and cytoplasmic ribosomes
INTRODUCTION
A reduction in muscle mass and strength occurs both in
response to chronic disease and as part of normal human aging
(9), and loss of muscle function reduces quality of life by
limiting ability to perform normal daily tasks and is associated
with increased mortality (7, 36). One chronic disease for which
skeletal muscle wasting is a common comorbidity is chronic
obstructive pulmonary disease (COPD) (19), and similarly, in this
condition, wasting and reduced muscle function are associated
with poorer quality of life and increased mortality (8, 35).
Muscle function is affected both by the amount of muscle,
which predominantly affects strength (12), and its oxidative
capacity, which predominantly affects endurance. Muscle ox-
idative capacity is dependent on the number and function of
mitochondria in the tissue (31). In COPD patients, there is a
reduction in both muscle mass (33) and mitochondrial oxida-
tive capacity (13, 20). The loss of muscle mass arises from an
imbalance in protein turnover with a relative increase in protein
breakdown compared with protein synthesis, and diverse stud-
ies have reported changes in components of both degradative
and synthetic pathways, but, taken together, these data do not
convey a consistent conclusion suggesting that there are mul-
tiple factors that regulate mass (15).
There are also a number of studies examining changes in
mitochondria in the muscle of COPD patients. Together they
show both reduced mitochondrial density and mitochondrial
dysfunction. The factors contributing to reduced mitochondrial
density include reduced mitochondriogenesis with lower levels
of proliferator-activated receptor- coactivator-1 and mito-
chondrial transcription factor A. The molecular mechanisms
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leading to mitochondrial dysfunction are less clear. Reduced
activity of electron transfer complexes that contain mitochondri-
ally encoded proteins has been reported (37) as have changes in
the respiratory control ratio (29). Consistent with these observa-
tions, a recent transcriptomic analysis of COPD muscle showed
marked reduction in the expression of mitochondrial genes with
weighted gene correlation network analysis identifying a mito-
chondrially enriched gene module as a major factor associated
with pulmonary function and exercise capacity (41). Changes
were also seen in mitochondrial dysfunction associated with aging
and in patients with intensive care unit-acquired weakness
(ICUAW) (3, 14, 37).
One mechanism by which this change in the activity of
mitochondrial complexes that contain mitochondrially encoded
proteins may occur is through the inhibition of mitochondrial
translation. We recently showed that the microRNA (miRNA)
miR-542-3p inhibited the expression of mitochondrial ribo-
somal proteins, reduced mitochondrial rRNA in particular the
12S rRNA leading to a reduction in the 12S:16S mitochondrial
rRNA ratio, and reduced mitochondrial membrane potential
(11). This miRNA also targets cytoplasmic ribosomal proteins
suggesting that it would reduce maximal protein synthesis so
may contribute to a loss of muscle mass. Elevation of this
miRNA was observed in a small cohort of patients with severe
COPD, but the association of this miRNA with muscle func-
tion in COPD patients was not analyzed further in our prior
report (11). We also did not quantify the expression of mito-
chondrial RNAs to determine whether there was evidence for
mitochondrial ribosomal stress in COPD patients.
The current study therefore was designed to investigate the
expression of miR-542-3p/5p in the quadriceps of a second, larger
cohort of COPD patients, compare it to physical performance, and
quantify the expression of mitochondrial rRNAs. The expression
of these miRNAs was determined in the muscle of healthy older
individuals to identify any association with muscle dysfunction in
the absence of overt disease. We also determined the effect of
miR-542-3p on cytoplasmic protein synthesis.
METHODS
Subjects
All subjects gave informed consent before inclusion in the relevant
study, which was approved by the appropriate ethical review bodies as
detailed for each cohort. All procedures were carried out in accor-
dance with the Helsinki Declaration.
COPD cohort. COPD subjects (n  52) and controls (n  16)
were part of a larger study described by Natanek et al. (23). The
patients had COPD according to the Global Initiative in Obstruc-
tive Lung Disease (GOLD) guidelines 2004 (30) and were enrolled
from clinics at the Royal Brompton Hospital. Patients with a
diagnosis of heart, renal, or liver failure, a systemic inflammatory
or metabolic disorder, or a moderate/severe exacerbation (i.e.,
requiring antibiotics, oral steroids, or hospitalization) in the pre-
ceding 4 wk were excluded. Healthy age-matched controls (16 in
total) were recruited by advertisement. All subjects gave written
informed consent and the protocol was approved by the Royal
Brompton and Harefield National Health Service Trust Research
Ethics Committee (Studies 06/Q0404/35 and 06/Q0410/54). Mea-
surements of lung volume, using plethysmography; carbon mon-
oxide transfer factor, using the single breath technique (Compact-
Lab, Jaeger, Germany); and postbronchodilator spirometry were
performed according to American Thoracic Society/European Re-
spiratory Society guidelines (40). Blood gas tensions were mea-
sured in arterialized capillary earlobe blood. Bioelectrical imped-
ance was used to determine fat-free mass index (FFMI; Bodystat
1500, Bodystat, UK) as described previously (34).
Quadriceps strength was determined by measuring supine isometric
maximal voluntary contraction (MVC) as described previously (35)
and physical performance measured as 6-min walk distance, 5 min after
bronchodilator treatment [American Thoracic Society 2002 guidelines
(1)]. Vastus lateralis muscle biopsies were obtained under local anes-
thesia by percutaneous needle biopsy of the in the midthigh using
the Bergstrom technique (2).
Hertfordshire Sarcopenia Study cohort. The study protocol was
approved by the Hertfordshire Research Ethics Committee (study 07/
Q0204/68) and all participants gave written informed consent. Muscle
mass and strength together with gait speed and a timed-up-and go (TUG)
test were ascertained; Hertfordshire Sarcopenia Study (HSS) methods
have been previously described (25). Muscle biopsy was performed by
percutaneous conchotome biopsy of the vastus lateralis under local
anesthesia (24).
RNA Analysis
Quantification of rRNA. RNA was extracted using Trizol, and tran-
scripts were reverse transcribed into cDNA using random primers using
the Quantitect RT Kit (Qiagen) and quantified by real-time qRT-PCR as
described previously using the primers described in Table 1 (10). rRNA
expression was normalized to hypoxanthine phosphoribosyltransferase
(HPRT) expression (human samples) or to the geometric mean of HPRT
and 2-microglobin (cell culture samples) in the same sample using
the CT method.
Quantification of miRNAs. miRNAs were reverse transcribed using
MultiScribe Reverse Transcriptase and Megaplex RT Primers (human
pool A, Version 3.0; Applied Biosystems) according to the manufac-
turer’s instructions. The samples were heated to 85°C for 5min to
terminate the reactions then stored at 80°C. The cDNAs were
preamplified using Megaplex PreAmp Primers (Applied Biosystems)
for 12 cycles of 95°C for 15 s and 60°C for 4 min, and the reactions
were terminated by heating to 99.9°C for 10 min. The resulting cDNA
was diluted to 100 	l by addition of 0.1
 TE buffer pH 8.0 (Qiagen)
and stored at 80°C. Primers and probes for miR-542-3p and miR-
542-5p were purchased for each test gene from Applied Biosystems, and
amplification was carried out according to the manufacturer’s instruc-
tions. Each reaction was performed in duplicate, and the average Ct value
was normalized to the corresponding geometric mean of U6 and RNU48
using the Ct method. RNA isolated from cells was analyzed using
single RT reactions.
Table 1. Primers used in this study
Target Forward Reverse
12S CCCAAACTGGGATTAGATACCC GTTTGCTGAAGATGGCGGTA
16S GCCTGTTTACCAAAAACATCAC CTCCATAGGGTCTTCTCGTCTT
HPRT GCTATAAATTCTTTGCTGACCTGCTG AATTACTTTTATGTCCCCTGTTGACTGG
2-Microglobulin TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCTAAGT
HRPT, hypoxanthine phosphoribosyltransferase.
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Cell Culture
HLCN-M2 cells were maintained in skeletal muscle growth me-
dium (PromoCell) supplemented with 20% FCS, as previously de-
scribed (42). All experiments were performed on cells as myoblasts.
RNA was extracted using Trizol; mRNA and miRNAs were quanti-
fied as described above.
miRNA transfection. Six-thousand two-hundred and fifty cells were
seeded into each well of a 96-well plate. After 24 h, cells were
transfected with mirVana miRNA mimics with each well treated with
a mixture containing 0.5 	l of 20 	M mirVana miRNA mimic(s) and
0.5 	l Lipofectamine 2000 (ThermoFisher) prepared according to the
manufacturer’s instructions.
RNA extraction. Forty-eight hours after microRNA transfection,
RNA was extracted from LHCN-M2 cells using the CellAmp Direct
RNA Prep Kit (TaKaRa) according to the manufacturer’s instructions.
miRNA and rRNA were analyzed as described above.
Protein Analysis
Western blotting. Western blotting for RPS23 was carried out as
previously described (18) but using rabbit anti-RPS23 (Novus) at
1:100.
Protein synthesis. Forty-eight hours after miRNA transfection,
LHCN-M2 cells were serum and leucine-starved by incubation in
leucine-free DMEM. Two hours later, the medium was replaced
with leucine-containing DMEM supplemented with 130 nM of
IGF-1 (Cambridge Bioscience), and the cells were incubated for 45
min before addition of 100 ng/ml puromycin (Sigma) and har-
vested 30 min later, and protein was extracted. Three-hundred
nanograms of the extracted protein were diluted in 200 	l of 50
mM sodium bicarbonate and incubated in a 96-well plate well at
37°C for 2 h. The wells were washed (1 time in PBS) then blocked
with 200 	l PBS containing 5% BSA (wt/vol; PBS-BSA) for 30
min at room temperature. The solution was replaced with 100 	l of
100 ng/ml anti-puromycin (Millipore) diluted in PBS-BSA and the
samples were incubated for 1 h at room temperature. After being
washed two times in PBS, 100 	l of sheep anti-mouse (GE
Healthcare) was added at a 1/10,000 dilution in PBS-BSA. The
samples were washed four times in PBS before 100 	l of TMB
substrate (Sigma) was added, and the samples were incubated for
15 min. The reaction was stopped with 100 	l of stopping solution
(Sigma), and absorbance was determined at 450 nm.
Statistical Analysis
Gene expression data from human studies were log transformed
to stabilize variance and produce a normal distribution. Gene
expression data from in vitro studies were normalized to the mean
value for the appropriate control data set. Statistical analysis was
performed in Aabel (Gigawiz). Pearson correlations were used to
identify linear correlations after visual inspection of scatter plots.
Differences between groups were calculated by Student’s t-test for
normally distributed data and by Mann-Whitney U-test for non-
parametric data. Differences between multiple groups were iden-
tified by ANOVA with post hoc testing using a Bonferroni-Dunn
correction.
Bioinformatic Analysis
The quadriceps gene expression profiles of the majority of the
patients included in this study have been published previously (n 
41 patients and n  12 controls) (41). Correlation analysis was
performed within the WGCNA R package using robust biweight
midcorrelation to determine the correlation coefficients. Gene set
enrichment analysis was then performed to identify groups of
genes associated with the miRNAs comparing the correlation
coefficients for genes that were significant at P  0.02. To
determine the association of the miRNAs with mRNAs for mito-
chondrial ribosomal proteins, the geometric mean of the target
proteins individually and for all detected mitochondrial small
ribosomal proteins was calculated and compared with miR-542
expression in the same sample.
RESULTS
Patient Demographics
By design and consistent with a diagnosis of COPD, the
patients had poorer lung function than controls by all mea-
sures. The patient cohort included 11 patients with GOLD
1–2, 25 patients with GOLD 3, and 16 patients with GOLD
4 COPD. There was no difference in FFMI between patients
and controls, but patients had poorer exercise performance
measured both as 6-min walk distance and quadriceps MVC.
The patients also had lower daily activity levels than the
controls. The demographic data are presented in Table 2.
Expression of miR-542-3p/5p in the Quadriceps of Patients
with COPD
The expression of miR-542-3p/5p was determined in a
cohort of COPD patients (both sexes and all GOLD grades)
and controls. Both miRNAs were elevated in the muscle of
COPD patients compared with controls (542-3p: 5.5-fold, P 
0.001 and 542-5p: 5.9-fold, P  0.001; Fig. 1, A and B) and
highly correlated with each other (r  0.95, P  0.001).
Quadriceps expression of these miRNAs was inversely asso-
ciated with lung function measured either as transfer capacity
of the lung for CO percent predicted (TLCO%) (542-3p:
r  0.60, P  0.001 and 542-5p: r  0.62, P  0.001 for
the whole cohort; and 542-3p: r  0.44, P  0.001 and
542-5p: r  0.42, P  0.002, for the patients alone; Fig. 1,
C and D) or as forced expiratory volume in 1 s in percent
predicted (FEV1%) 542-3p: r  0.54, P 0.001 and 542-5p:
Table 2. Physiological characteristics of the COPD cohort
Control (n  16) COPD (n  52)
Sex (male/female) 7, 9 30, 22
Age, yr 66  8 66  8
Smoking history,a
pack-yr 0 (0, 10) 44 (30, 60)***
Weight,a kg 67 (61, 74) 66 (59, 77)
BMI,a kg/m2 24.8 (23.5, 26.2) 23.3 (21.4, 26.2)
FFMI,a kg/m2 16.1 (15.3, 17.2) 15.3 (14.5, 16.8)
FEV1,a %pred 107.6 (100.6, 112) 40.7 (27.2, 48.4)***
RVTLC 38  6 59  8***
TLCO,a %pred 92.3 (83.0, 98.1) 45.0 (32.1, 52.4)***
6-Min walk, m 621  84 387  125***
6-Min walk, %pred 126  12 76  24***
PV˙ O2,a %pred 99 (88, 111) 46 (38, 58)***
SGRQ,a 2 (0, 8) 54 (45, 61)***
Quadriceps MVC, kg 34.7  10.6 28.2  8.9*
Quadriceps MVC, %pred 78  19 63  14**
Locomotion time,a
min/12 h
96 (84, 127) 41 (26, 56)***
Movement time, %12 h 23  6 13  5***
Values are means SE or median (interquartile range). BMI, body mass index;
FFMI, fat free mass index; FEV1, forced expiratory volume in 1 s; RVTLC, ratio
of the reserve volume to total lung capacity; TLCO, transfer capacity of the lung for
CO; SGRQ, St George’s respiratory questionnaire; MVC, maximal voluntary
contraction. *P 0.05. **P 0.01. ***P 0.001. Significance determined by
Student’s t-test except for variables denoted a, where P values were calculated
by Mann Whitney U-test.
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r  0.59, P  0.001 for the whole cohort; and 542-3p:
r  0.38, P  0.006 and 542-5p: r  0.29, P  0.035, for
the patients only; Fig. 1, E and F). Furthermore, the miRNAs
were inversely proportional to exercise performance measured
as 6-min walk distance expressed, as percent predicted, in both the
whole cohort (542-3p: r0.58, P  0.001 and 542-5p:
r0.59, P  0.001; Fig. 2, A and B) and in the patients alone
(542-3p: r0.037, P  0.006 and 542-5p: r0.35, P 
0.012). Although both miRNAs were weakly inversely associated
with strength in the patients and controls considered together
(measured as MVC% predicted, 542-3p: r  0.37, P 0.002
and 542-5p: r  0.43, P 0.001; Fig. 2, C and D) and FFMI
(542-3p: r  0.27, P  0.028 and 542-5p: r  0.26, P 
0.034; Fig. 2, E and F), neither miRNA was associated with
strength in the patients alone (542-3p: r  0.22, P  0.109
and 542-5p: r  0.27, P  0.054) or FFMI (542-3p:
r  0.177, P  0.210 and 542-5p: r  0.172, P  0.224).
The associations did not differ significantly between men
and women (data not shown).
To further determine whether the expression of these
miRNAs was also associated with muscle function in
healthy seniors, we also measured the expression of the
miRNAs in samples from the HSS (demographics in Table 3).
In normal healthy older men from the HSS, both miRNAs were
associated with poorer physical performance as indicated by
3-min walk time and time to up and go 6-min TUG test (Fig.
3, A–D). Although neither miRNA was associated with FFMI
in the HSS participants, both were elevated in those defined
as having sarcopenia (Fig. 3, E and F).
Fig. 1. Expression of the miR-542-3p and
miR542-5p is increased in the quadriceps of
chronic obstructive pulmonary disease (COPD)
patients and associated with disease severity.
miR-542-3p and miR-542-5p were quanti-
fied in muscle biopsies from patients with
COPD (n  52) and controls (n  16). A
and B: miR-542-3p (A) was elevated 5.5-
fold (P  0.001) and miR-542-5p (B) was
elevated 5.9-fold (P  0.001). AU, arbitrary
units. C–F: comparison of the expression of
both microRNAs (miRNAs) with measure-
ments of lung function transfer factor for
CO percent predicted (TLCO%; C and D)
and forced expiratory volume in 1 s in per-
cent predicted (FEV1%; E and F) showed
that expression of these miRNAs in the
quadriceps was associated with disease se-
verity. miRNA expression was normalized
to the expression of U6 and RNU48 in the
same samples. Data were analyzed by t-test
and Pearson correlations shown are for the
entire cohort. Patients are shown as closed
circles and controls as empty circles.
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Do COPD Patients Show Evidence of Mitochondrial
Ribosomal Stress?
In patients with established ICUAW the marked elevation of
miR-542-3p was associated with a significant reduction in 12S
rRNA levels compared with 16S rRNA levels indicative of
mitochondrial ribosomal stress (11). To determine if increased
miR-542-3p in the quadriceps of COPD patients was associated
with evidence of mitochondrial ribosomal stress in COPD, we
quantified the expression of 12S and 16S rRNA in the patients
with COPD (n  40) and controls (n  14) for which we
had appropriate cDNAs. There was a reduction in both the
12S and 16S rRNAs that was larger in the 12S rRNA
resulting in a significant reduction in the 12S:16S ratio
(Fig. 4).
miR-542 Expression Is Associated with Mitochondrial Gene
Expression and P53 Activity in Patients
We have previously shown that overexpression of miR-542
leads to a reduction in the 12S:16S ratio in cells in culture and
in the muscle of mice (11). This observation suggests that
increased miR-542 in the muscle of patients with COPD may
contribute to the loss of mitochondrial function in COPD
Table 3. Physiological characteristics of HSS cohort
Nonsarcopenic (n  59) Sarcopenic (n  5)
Weight,a kg 83 (72, 92) 69 (66, 71)*
BMI,a kg/m2 27 (25, 29) 26 (25, 27)
FFMI,a kg/m2 18.5 (17.5, 19.3) 16.2 (15.9, 17.1)**
FEV1,a %pred 106 (98, 117) 108 (103, 111)
TUG time, s 10.4  1.7 13.7  4.7**
3-Min walk time,a s 2.7  0.4 3.4  1.0**
Values are means  SE or median (interquartile range). HSS, Hertford-
shire Sarcopenia Study (HSS); BMI, body mass index; FFMI, fat free mass
index; FEV1, forced expiratory volume in 1 s; TUG time, time to “get up
and go.” *P  0.05. **P  0.01. Significance determined by Student’s t-test
except for variables denoted a, where P values were calculated by Mann-
Whitney U-test.
Fig. 2. The miR-542-3p and 542-5p are associ-
ated with physical performance in chronic ob-
structive pulmonary disease (COPD). miR-
542-3p and miR-542-5p were quantified in mus-
cle biopsies from patients with COPD (n  52)
and controls (n 16). A and B: comparison of the
expression quadriceps of both microRNAs
(miRNAs) with 6-min walk distance (6MW)
%predicted showed an inverse association
both in the whole cohort and in the patients
as a subgroup [miR-542-3p, (A) and miR-
542-5p (B)]. AU, arbitrary units. C and D:
comparison of the expression of both miRNAs
with strength (maximal voluntary contraction
(MVC) %predicted showed a weak inverse
association in the whole cohort but not in the
patients as a subgroup [miR-542-3p (C) and
miR-542-5p (D)]. E and F: comparison of
the expression quadriceps of both miRNAs
with FFMI showed a weak inverse associa-
tion in the whole cohort but not in the pa-
tients as a subgroup [miR-542-3p (E) and
miR-542-5p (F)]. miRNA expression was
normalized to the expression of U6 and
RNU48 in the same samples. Pearson corre-
lation coefficients shown are for the entire
cohort. Patients are shown as closed circles
and controls as empty circles.
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muscle. To determine whether miR-542 was associated with
mitochondrial gene expression, the recently published array
data (41) from samples included in this study was compared
with the miRNA expression reported here. Biweight midcor-
relation coefficients were calculated for all detected genes
using the WGCNA R package and correlations that reached a
statistical significance of 0.02 were used for gene set enrich-
ment analysis. The gene set most negatively associated with
miR-542 was mitochondrial genes, and this observation was
true whether the analysis was performed using the patients only
or the whole cohort (Table 4). The gene sets positively corre-
lated with miR-542 included sets associated with the inflam-
matory response raising the possibility that some aspect of
inflammatory signaling contributes to the expression of miR-
542 (Table 4). However, there was no simple association of
miR-542 expression with inflammatory cytokines (IL-2, IL-6,
IL-8, or TNF-) or with global DNA bound NF-B p50 or p65
indicating that these cytokines alone are not sufficient to
explain the association of miR-542 with disease severity (data
not shown). The positively correlated gene sets also included
the gene set for P53 activity. As mitochondrial ribosomal stress
has been shown to promote P53 activation this observation is
consistent with miR-542-driven mitochondrial ribosomal stress
activating P53.
Does miR-542-3p Inhibit Protein Synthesis?
miR-542-3p inhibits the expression of a number of proteins
that make up the cytoplasmic small ribosomal subunit promoting
cytoplasmic ribosomal stress and reducing 18S rRNA expression
(39). Consequently, this miRNA should suppress maximal protein
synthesis. We therefore confirmed the reduction in RPS23 and
18S rRNA in muscle cells (Fig. 5, A and B) and determined the
effect of miR-524-3p on leucine- and IGF-1-stimulated pro-
teins synthesis by quantifying puromycin incorporation. Trans-
fection of LHCN-M2 muscle myoblasts with miR-542-3p
Fig. 3. The miR-542-3p and -5p are associ-
ated with physical performance in older peo-
ple. A–D: miR-542-3p and miR-542-5p were
quantified in quadriceps biopsies from older
individuals enrolled in the Hertfordshire Sar-
copenia Study (HSS) (n  64) and corre-
lated with physical performance measured
using the timed up and go test (A and B) and
3-min gait speed (C and D). AU, arbitrary
units. A–D: both miR-542-3p (A and C) and
miR-542-5p (B and D) were associated with
poor physical performance on both tests. E
and F: furthermore, in the patients identified
as sarcopenic according to European Working
Group on Sarcopenia in Older People guide-
lines (n  5) both microRNAs (miRNAs)
[miR-542-3p (E) and miR-542-5p (F)] were
elevated compared with those who were not
sarcopenic (n  59). The data shown for
miR-542-3p are taken from all 64 samples;
however, 4 samples did not amplify for miR-
542-5p (3 nonsarcopenic and 1 sarcopenic),
so these data come from 56 control and 4
sarcopenic individuals. miRNA expression
was normalized to the expression of U6 and
RNU48 in the same samples. Pearson corre-
lation coefficients shown and statistical
difference was calculated by Student’s t-
test.
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decreased puromycin incorporation (Fig. 5C) suggesting that
miR-542-3p inhibited the formation of the small ribosomal
subunit and inhibited protein synthesis.
DISCUSSION
The data presented here show that increased expression of
miR-542-3p and miR-542-5p is associated with muscle dys-
function in COPD patients. Quadriceps expression of these
miRNAs is associated with lung function measured as either
TLCO% predicted or FEV1% predicted. Consistent with pro-
motion of mitochondrial ribosome stress by miR-542-3p, ex-
pression of the 12S rRNA was reduced. Furthermore, the
expression of miR-542-3p/5p was inversely associated with the
expression of mitochondrial genes and positively associated
with the genes associated with activation of the p53 pathway,
consistent with an association with mitochondrial dysfunction
and ribosomal stress. We also show that miR-542-3p can
reduce RPS23 and 18S rRNA expression and inhibit protein
synthesis in muscle cells. Taken together, the data suggest that
disease situated in the lung promotes the muscle expression of
miR-542-3p/5p where it promotes mitochondrial dysfunction
and inhibits protein synthesis. The association of miR-542-
3p/5p with inflammatory signaling raises the possibility that in
this context inflammatory mediators released as part of, or in
response to, lung disease promote miR-542-3p/5p expression but
the lack of correlation of miRNA expression with the classical
mediators of inflammatory signaling mean that the factors under-
lying this association remain to be identified. The promoter that
controls the expression of miR-542 has yet to be confirmed but the
close proximity of this miRNA to the miR-424-503 host gene
suggests that these genes are coexpressed from the same pro-
moter. This suggestion is supported by relatively tight correla-
tion of the expression of miR-542 expression with miR-424 in
all the studies we have performed. This region of DNA con-
tains multiple binding sites for STAT, NF-B, and glucocor-
ticoid receptors suggesting that it functions as part of a stress
response system. An alternative possibility for the elevation of
these miRNAs in muscle is delivery from another tissue via
exosomes. However, this route would require sufficient pro-
duction of these miRNAs and exosomes in an organ to
increase the levels in muscle sixfold and where skeletal
muscle accounts for ~40% of the body mass.
Table 4. Gene set enrichment for genes associated with
miR-542
Hallmark NES NOM P Value FDR Q Value
Positive
Epithelial mesenchymal transition 4.212 0.000 0.000
Interferon gamma response 2.879 0.000 0.000
IL2 STAT5 signaling 2.716 0.000 0.000
Inflammatory response 2.621 0.000 0.000
Apoptosis 2.616 0.000 0.001
Coagulation 2.605 0.000 0.001
Complement 2.421 0.000 0.002
TNF signaling via NF-B 2.087 0.006 0.013
UV response Dn 2.054 0.002 0.014
Hypoxia 1.913 0.008 0.022
Apical junction 1.775 0.020 0.042
P53 pathway 1.767 0.028 0.040
KRAS signaling up 1.762 0.015 0.038
Negative
Oxidative phosphorylation 5.046 0.000 0.000
Fatty acid metabolism 3.058 0.000 0.000
Adipogenesis 2.231 0.000 0.002
NES, normalized enrichment score; NOM, nominal; FDR, false discovery
rate.
Fig. 4. Mitochondrial RNA expression is re-
duced in chronic obstructive pulmonary disease
(COPD) patients. Quadriceps expression of
12S and 16S rRNAs were quantified in samples
from COPD (n  40) and controls (n  14). A
and B: expression of both the 12S rRNA (A)
and 16S rRNA (B) were reduced in the patients
compared with controls. AU, arbitrary units. C:
the reduction in the 12S rRNA was larger than
that in the 16S rRNA leading to a reduction in
the 12S:16S ratio (C).
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Significance of the Findings
A significant proportion of COPD patients report leg fatigue
as a more important locus of exercise limitation than breath-
lessness (16, 28). A well-recognized cause of this early fatigue
is a reduction in mitochondrial function and oxidative capacity.
One intriguing component of this reduction in oxidative capac-
ity is a greater reduction in the activity of mitochondrial
complex I and IV, which require translation to occur both in
the cytoplasm and mitochondria, compared with complex II
which only requires translation in the cytoplasm (37). Conse-
quently, a relative reduction in translation in mitochondria
would lead to a greater reduction in the activity of complexes
I and IV. This reduction in activity of electron transfer com-
ponents requiring mitochondrial translation is also seen in
sarcopenia where an accumulation of mutations in the mito-
chondrial genome has been suggested to contribute (4, 38). Our
previous study showing that miR-542-3p suppressed the ex-
pression of mitochondrial ribosomal proteins and the 12S
rRNA provided an additional mechanism by which mitochon-
drial protein synthesis could be suppressed and mitochondrial
dysfunction could occur (11). Furthermore, this reduction in
the ability to form functional mitochondrial ribosomes also
reduced the levels of the small ribosomal RNA (12S) compared
with the large ribosomal subunit RNA (16S). Our observation
of a reduced 12S:16S rRNA ratio is consistent with such a
mechanism contributing to the mitochondrial dysfunction in
COPD patients. This effect of miR-542-3p on mitochondrial
function is sufficient to explain the association of miR-542-3p
with physical performance that we see both in the COPD
patients and in the healthy older individuals from the HSS.
This mechanism does not appear to be restricted to COPD
patients as we have also demonstrated similar effects in pa-
tients with ICUAW (11), in whom there is also preferential loss
of complex I and complex IV activity. Taken together, these
data suggest that changes mediated by miR-542-3p are not
disease specific but a more general pathophysiologic process.
In its most extreme form, the effects of inhibition of mitochon-
drial translation can be seen via the occasional gene mutations
in humans causing an inability to synthesize the small subunit
of the mitochondrial ribosome (21, 32). These mutations have
a similar, but more marked, effect on the electron transfer chain
and on 12S rRNA levels to that observed here and ICUAW.
The observation that miR-542-3p-mediated muscle dysfunction
can complicate ICUAW, COPD, and indeed, “normal” aging
suggests a currently unknown mechanism by which diverse eti-
ologies can trigger a single underlying molecular mechanism.
Immobility (or more specifically contractile history) would be one
candidate since it is present to some extent in all three condi-
tions. However, we did not see any association of miR-542-3p
expression with daily physical activity. Other possible candi-
dates might include inflammation that is present in the inten-
sive care unit and at least episodically in COPD (at time of
acute exacerbation), and as demonstrated in this study, there is an
association of miR-542 expression with markers of the activation
of inflammatory signaling in the muscle but no association with
classic inflammatory cytokines. Identification of the mecha-
nisms leading to increased expression of miR-542-3p would
be insightful and could offer a novel therapeutic approach to
this condition.
Fig. 5. The miR-542-3p suppresses the ex-
pression of RPS23 and inhibits protein syn-
thesis in muscle cells. LHCN-M2 cells were
transfected with miR-542-3p or scrambled
control as described in Methods and incu-
bated for 2 days. A: transfected cells were
lysed and the expression of RPS23 was de-
termined by Western blotting. The experi-
ment was repeated 3 times and expression of
RPS23 was normalized to Ponceau S stain.
RPS23 expression was suppressed by trans-
fection with the microRNAs. AU, arbitrary
units. B: 18S rRNA was quantified and nor-
malized to the geometric mean of 2-micro-
globiulin and hypoxanthine phosphoribosyl-
transferase (HPRT) in transfections performed
in hextuplicate and the experiment repeated 3
times. miR-542-3p suppressed 18S rRNA ex-
pression. C: protein synthesis was analyzed by
quantifying puromycin incorporation as de-
scribed in METHODS with the transfections
performed in quadruplicate and the experi-
ment repeated 3 times. Puromycin incorpo-
ration was lower in miR-542-3p-transfected
cells than in control transfected cells indicating
a suppression of protein synthesis. Data are
presented as means SE. P values were cal-
culated by Student’s t-test. 3p, miR-542-
3p; 3p  Ant, miR-542-3p  antagomiR;
cont, control; RPS23, ribosomal protein
S23; untrans, untransfected.
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Critique of the Method
Even though we showed that miR-542-3p can suppress
maximal protein synthesis in vitro, expression of this
miRNA was not strongly associated with FFMI. There are a
number of likely reasons for this lack of association. First,
FFM is not a good tool for detecting quadriceps weakness in
COPD (22), presumably because the muscle wasting ob-
served in COPD is regional in nature. Second, there are
multiple inputs into the regulation of protein synthesis and
the increase of miR-542-3p would have to be one of the
predominant regulators for a significant association to be
observed. For example, we have already shown that an
miRNA from the same locus as miR-542 (miR-424-5p)
suppresses the expression of rRNAs by targeting PolR1A
the RNA polymerase required for rRNA synthesis and
UBTF, a key transcription factor that activates RNA poly-
merase I (5) as well as targeting IGF-1 (6). This miRNA
while closely correlated with miR-542-3p expression in
COPD and ICUAW is associated with FFMI in the COPD
patients suggesting that suppression of rRNA synthesis is
more important in terms of protein synthesis than the effects
of miR-542 on small ribosomal protein expression. Third,
altering the number or activity of ribosomes by one miRNA
is also unlikely to be the only mechanism contributing to
protein synthesis. For example, increasing or reducing the
number of nuclei will affect the capacity to transcribe all
genes implicating the rate of regeneration in muscle reten-
tion. Again, regeneration is controlled by miRNAs, and we
have shown that the expression of the imprinted miRNAs
from a cluster on chromosome 19 (C19MC; expressed from
the paternal chromosome) and miR-675 (expressed from the
maternal chromosome) associate with FFMI in COPD pa-
tients but not controls (17). Finally, the loss of muscle mass
over time is not only due to reduced protein synthesis but
protein breakdown also contributes. The rate of protein
breakdown will be dependent on the strength of any signal
promoting atrophy and the sensitivity of an individual to
that signal. Previous studies have shown that levels of
GDF-15, a protein that promotes muscle breakdown and
reduces appetite, are associated with muscle mass and func-
tion in COPD (26) suggesting that this is one proatrophic
signal contributing to muscle breakdown. Variation in the
sensitivity to atrophic signals also comes from miRNA
dependent regulation of the expression of components of
signaling pathways with miR-422a reducing the activity of
myostatin/TGF- signaling by suppressing SMAD4 (27).
The work presented here is a cross-sectional study into
the expression of a miRNA and mitochondrial rRNAs in
patients with COPD. We therefore cannot prove that the
associations or relationships are causal. We are also unable
to confirm that there is reduced mitochondrial function in
the individual samples that we examined as there is insuf-
ficient sample available. However, our in vitro and animal
studies presented here and in our previous study (11) are
consistent with such a role for the miRNAs and there are a
number of studies showing reduced mitochondrial function
in patients with COPD (reviewed in Ref. 20). Furthermore,
we identify an altered 12S:16S ratio in the COPD patients
consistent with mitochondrial dysfunction. The data are also
consistent with the miRNA suppressing maximal protein
synthetic capacity. This altered miRNA and rRNA expres-
sion pattern is also seen in the ICUAW patients we have also
studied.
In conclusion, our data identify the targeting of both
cytoplasmic and mitochondrial ribosomal proteins by miR-
542-3p as contributing to the loss of physical performance
in patients with COPD. This reduction in ribosomal proteins
reduces the availability of small ribosomal subunits inhib-
iting protein synthesis in each compartment. The expression
of these miRNAs is elevated in response to components of
the disease process that are known to cause tissue hypoxia, and
in vitro data reported here confirm this as a plausible mecha-
nism.
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